These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 29021138)

  • 21. In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma.
    Kaushik AK; Tarangelo A; Boroughs LK; Ragavan M; Zhang Y; Wu CY; Li X; Ahumada K; Chiang JC; Tcheuyap VT; Saatchi F; Do QN; Yong C; Rosales T; Stevens C; Rao AD; Faubert B; Pachnis P; Zacharias LG; Vu H; Cai F; Mathews TP; Genovese G; Slusher BS; Kapur P; Sun X; Merritt M; Brugarolas J; DeBerardinis RJ
    Sci Adv; 2022 Dec; 8(50):eabp8293. PubMed ID: 36525494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
    Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
    Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
    Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
    Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
    Thompson RM; Dytfeld D; Reyes L; Robinson RM; Smith B; Manevich Y; Jakubowiak A; Komarnicki M; Przybylowicz-Chalecka A; Szczepaniak T; Mitra AK; Van Ness BG; Luczak M; Dolloff NG
    Oncotarget; 2017 May; 8(22):35863-35876. PubMed ID: 28415782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
    Qie S; Yoshida A; Parnham S; Oleinik N; Beeson GC; Beeson CC; Ogretmen B; Bass AJ; Wong KK; Rustgi AK; Diehl JA
    Nat Commun; 2019 Mar; 10(1):1296. PubMed ID: 30899002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CB-839 induces reversible dormancy in lung tumor-cells.
    Jamshidi-Parsian A; Jenkins SV; Tran A; Bragg A; Davis R; Griffin C; Siegel E; Dings RPM; Griffin RJ; Boysen G
    Eur J Pharmacol; 2024 Nov; 982():176912. PubMed ID: 39159716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
    Elgogary A; Xu Q; Poore B; Alt J; Zimmermann SC; Zhao L; Fu J; Chen B; Xia S; Liu Y; Neisser M; Nguyen C; Lee R; Park JK; Reyes J; Hartung T; Rojas C; Rais R; Tsukamoto T; Semenza GL; Hanes J; Slusher BS; Le A
    Proc Natl Acad Sci U S A; 2016 Sep; 113(36):E5328-36. PubMed ID: 27559084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism.
    Shroff EH; Eberlin LS; Dang VM; Gouw AM; Gabay M; Adam SJ; Bellovin DI; Tran PT; Philbrick WM; Garcia-Ocana A; Casey SC; Li Y; Dang CV; Zare RN; Felsher DW
    Proc Natl Acad Sci U S A; 2015 May; 112(21):6539-44. PubMed ID: 25964345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
    Masamha CP; LaFontaine P
    J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterogeneity of glutamine metabolism in acquired-EGFR-TKI-resistant lung cancer.
    Kim S; Jeon JS; Choi YJ; Baek GH; Kim SK; Kang KW
    Life Sci; 2022 Feb; 291():120274. PubMed ID: 34990648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetic Modeling of
    Viswanath V; Zhou R; Lee H; Li S; Cragin A; Doot RK; Mankoff DA; Pantel AR
    J Nucl Med; 2021 Aug; 62(8):1154-1162. PubMed ID: 33277391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The activation loop and substrate-binding cleft of glutaminase C are allosterically coupled.
    Li Y; Ramachandran S; Nguyen TT; Stalnecker CA; Cerione RA; Erickson JW
    J Biol Chem; 2020 Jan; 295(5):1328-1337. PubMed ID: 31871054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2'-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs.
    Preston TJ; Henderson JT; McCallum GP; Wells PG
    Mol Cancer Ther; 2009 Jul; 8(7):2015-26. PubMed ID: 19567822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glutamine Metabolism Heterogeneity in Glioblastoma Unveils an Innovative Combination Therapy Strategy.
    Fu H; Wu S; Shen H; Luo K; Huang Z; Lu N; Li Y; Lan Q; Xian Y
    J Mol Neurosci; 2024 May; 74(2):52. PubMed ID: 38724832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
    Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
    Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
    Chen Z; Li D; Xu N; Fang J; Yu Y; Hou W; Ruan H; Zhu P; Ma R; Lu S; Cao D; Wu R; Ni M; Zhang W; Su W; Ruan BH
    J Med Chem; 2019 Jan; 62(2):589-603. PubMed ID: 30543285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer.
    Zacharias NM; McCullough C; Shanmugavelandy S; Lee J; Lee Y; Dutta P; McHenry J; Nguyen L; Norton W; Jones LW; Bhattacharya PK
    Sci Rep; 2017 Nov; 7(1):16159. PubMed ID: 29170516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glutamine deprivation plus BPTES alters etoposide- and cisplatin-induced apoptosis in triple negative breast cancer cells.
    Chen L; Cui H; Fang J; Deng H; Kuang P; Guo H; Wang X; Zhao L
    Oncotarget; 2016 Aug; 7(34):54691-54701. PubMed ID: 27419628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
    Reustle A; Menig LS; Leuthold P; Hofmann U; Stühler V; Schmees C; Becker M; Haag M; Klumpp V; Winter S; Büttner FA; Rausch S; Hennenlotter J; Fend F; Scharpf M; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Clin Transl Med; 2022 Jun; 12(6):e883. PubMed ID: 35678045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.